Sun Pharma launches Favipiravir at most affordable price

04 August 2020 | News

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

Mumbai based Sun Pharmaceutical Industries Limited recently announced that it has launched FluGuard® (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India.

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

Kirti Ganorkar, CEO of India Business, Sun Pharma commented, "With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard® at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India's pandemic response."

The company will work closely with the government and medical community to ensure the availability of FluGuard® to patients across the country. The stocks of FluGuard® will be available in the market from this week.